Invasive Aspergillosis Drug Pipeline Report 2022: Comprehensive Insights on Active Companies and Pipeline Drugs Featuring F2G, SCYNEXIS, Pulmocide, & TFF Pharmaceuticals - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 20, 2022--
The “Invasive Aspergillosis - Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Invasive Aspergillosis pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth Invasive Aspergillosis commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Invasive Aspergillosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Invasive Aspergillosis Emerging Drugs Chapters
This segment of the Invasive Aspergillosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Invasive Aspergillosis Emerging Drugs
Olorofim (formerly F901318) is F2G’s leading candidate from this class and has fungicidal activity against a broad range of mould infections including a variety of rare and resistant moulds that cause life-threatening infections for which current therapies have limitations or are ineffective.
Olorofim has received orphan drug status from the European Medicines Agency and orphan drug status, Qualified Infectious Disease Product (QIDP) designation and Breakthrough Therapy designation from FDA.
Ibrexafungerp (formerly SCY-078) is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. It has shown activity against Aspergillus and Candida, including against multidrug-resistant (MDR) species Candida auris as well as Pneumocystis. Ibrexafungerp combines the well-established activity of glucan synthase inhibitors with the flexibility of oral and IV formulations, offering a broad use across different settings (in-patient and out-patient).
Invasive Aspergillosis: Therapeutic Assessment
This segment of the report provides insights about the different Invasive Aspergillosis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Invasive Aspergillosis
There are approx. 3+ key companies which are developing the therapies for Invasive Aspergillosis. The companies which have their Invasive Aspergillosis drug candidates in the most advanced stage, i.e. phase III include, F2G.
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Invasive Aspergillosis.
- In the coming years, the Invasive Aspergillosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Invasive Aspergillosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Invasive Aspergillosis treatment market. Several potential therapies for Invasive Aspergillosis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Invasive Aspergillosis market size in the coming years.
- The in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Invasive Aspergillosis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
The report covers around 3+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Intravenous/ Subcutaneous
- Molecule Type
Products have been categorized under various Molecule types such as
- Antisense oligonucleotides
- Monoclonal antibody
- Recombinant protein
- Small molecule
- Stem Cell
- Product Type
Invasive Aspergillosis Report Insights
- Invasive Aspergillosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Invasive Aspergillosis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
- Pulmocide Ltd
- TFF Pharmaceuticals
- Voriconazole dry powder inhalation
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/7wjzpt
View source version on businesswire.com:https://www.businesswire.com/news/home/20221220005534/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 12/20/2022 10:12 AM/DISC: 12/20/2022 10:12 AM